Compare Quest Diagnostics Inc (DGX) vs Direxion Daily 20 Year Treasury Bull 3X Shares (TMF) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Quest Diagnostics Inc vs Direxion Daily 20 Year Treasury Bull 3X Shares — how do they compare? Quest Diagnostics Inc trades at $236.56 (market cap $26.21B), while Direxion Daily 20 Year Treasury Bull 3X Shares trades at $30.98. The key difference: Quest Diagnostics Inc pays a 1.45% dividend while Direxion Daily 20 Year Treasury Bull 3X Shares pays none, and Quest Diagnostics Inc is trading nearer its 52-week high, Direxion Daily 20 Year Treasury Bull 3X Shares nearer its low. Which is the better fit depends on your goals.
| DGX | TMF | |
|---|---|---|
Market Cap | $26.21B | — |
Sector | Health | Leveraged / Inverse |
52-Week High | $238.50 | $44.14 |
52-Week Low | $173.49 | $30.59 |
Enterprise Value | $31.97B | — |
Dividend Yield | 1.45% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Quest Diagnostics (DGX) trades at $237.63, down slightly by 0.3% today, but maintains strong momentum with three consecutive quarterly earnings beats and a raised 2026 outlook. The stock shows bullish technical signals with moving averages supporting upward trends, while fundamentals reveal solid revenue growth to $11.04 billion in 2025 and improving profit margins. Recent news highlights surging testing demand and AI implementation driving operational efficiency.
DGX presents a favorable investment case with analyst consensus price target of $249.50 offering 5% upside potential. Strong testing demand, strategic partnerships, and earnings momentum support growth, though elevated debt levels and margin pressures from lower-margin deals pose moderate risks. The stock's current valuation at 25.21 P/E appears reasonable given growth prospects.
TMF, the Direxion Daily 20+ Year Treasury Bull 3X ETF, trades at $30.93 with a 0.95% daily gain. Technical indicators show a bearish trend with moving averages and ADX signaling sell conditions, while oscillators remain neutral. The ETF faces significant fundamental challenges with unavailable valuation and profitability metrics, reflecting its leveraged structure that amplifies both gains and losses in long-duration treasuries.
The outlook for TMF remains high-risk due to its daily leverage reset mechanism, making it unsuitable for long-term holdings. While some analysts see potential at bond market lows, the dominant view cautions against current purchases given the substantial erosion of value over time, with $10,000 invested five years ago now worth approximately $1,527 according to 24/7 Wall Street analysis from June 2026.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Quest Diagnostics Inc
Quest Diagnostics is a leading independent provider of diagnostic testing, information, and services in the U.S. The company generates over 95% of its revenue through clinical testing, anatomic pathology, esoteric testing, and substance abuse testing with specimens collected at its national network of roughly 2,300 patient service centers, as well as multiple doctors offices and hospitals. The firm also runs a much smaller diagnostic solutions segment that provides clinical trials testing, risk assessment services, and information technology solutions.
Read more on DGX →About Direxion Daily 20 Year Treasury Bull 3X Shares
TMF is a leveraged ETF that seeks to provide 300% (3x) of the daily performance of the ICE U.S. Treasury 20+ Year Bond Index. It is a tactical instrument used by sophisticated traders to capitalize on declining interest rates or to hedge against equity market volatility. Due to its daily reset mechanism and high expense ratio, TMF is structurally designed for short-term speculation rather than long-term buy-and-hold investing.
Read more on TMF →
